Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evinacumab - Regeneron Pharmaceuticals

Next Previous
Drug Profile

Evinacumab - Regeneron Pharmaceuticals

Alternative Names: Evinacumab-dgnb; Evkeeza; REGN-1500

Latest Information Update: 16 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Regeneron Pharmaceuticals; Sanofi
  • Developer Regeneron Pharmaceuticals; Ultragenyx Pharmaceutical
  • Class Antihyperlipidaemics; Monoclonal antibodies
  • Mechanism of Action ANGPTL3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hyperlipoproteinaemia type II
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hyperlipoproteinaemia type II
  • Phase II Hypertriglyceridaemia

Most Recent Events

  • 14 Jul 2025 Registered for Hyperlipoproteinaemia type II (In infants, In children, In adults, In adolescents, In the elderly, Adjunctive treatment) in Canada (IV)
  • 18 Mar 2025 Ultragenyx Pharmaceutical completes a phase III trial in Hyperlipoproteinaemia type II in Canada (IV) (NCT05611528)
  • 06 Jan 2025 Launched for Hyperlipoproteinaemia type II in Japan (IV), before January 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top